

	AVASTIN	LUCENTIS	EYLEA	rolucizumab
Baseline				
Q2 2014	54%	46%	0%	
Q4	43%	32%	25%	
Q1 2015	49%	21%	30%	
Q2	44%	23%	33%	
Q3	36%	21%	43%	
Q4	38%	16%	46%	
Q12016	35%	19%	46%	
Q2	30%	23%	47%	
Q3	34%	17%	49%	
Q4	38%	19%	43%	
Q12017	43%	17%	40%	
Q2	38%	20%	42%	
Q3	44%	20%	36%	
Q4	38%	19%	43%	
Q12018	48%	15%	37%	
Q2	47%	18%	35%	
Q3	49%	14%	37%	
Q4	43%	17%	40%	
Q12019	35%	16%	49%	
Q2	42%	15%	43%	
Q3	40%	16%	44%	
Q4	45%	15%	40%	
Q1 2020	44%	15%	38%	2%
Q2	38%	21%	37%	4%
Q3	43%	14%	40%	3%
Q4	40%	16%	42%	2%
Q2 2021	36%	15%	48%	2%

Mylan v. Regeneron
 IPR2021-00881
 U.S. Pat. 9,254,338
 Exhibit 2283